KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Other Working Capital Changes (2016 - 2025)

Resmed (RMD) has disclosed Other Working Capital Changes for 17 consecutive years, with $106.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes rose 143.88% year-over-year to $106.4 million, compared with a TTM value of -$22.3 million through Dec 2025, down 126.43%, and an annual FY2025 reading of -$82.6 million, down 171.72% over the prior year.
  • Other Working Capital Changes was $106.4 million for Q4 2025 at Resmed, up from -$2.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $106.6 million in Q1 2022 and bottomed at -$79.4 million in Q1 2025.
  • Average Other Working Capital Changes over 5 years is $23.6 million, with a median of $22.2 million recorded in 2023.
  • The sharpest move saw Other Working Capital Changes skyrocketed 855.0% in 2022, then tumbled 1979.67% in 2025.
  • Year by year, Other Working Capital Changes stood at $7.0 million in 2021, then skyrocketed by 326.72% to $29.9 million in 2022, then grew by 9.09% to $32.6 million in 2023, then skyrocketed by 33.92% to $43.6 million in 2024, then surged by 143.88% to $106.4 million in 2025.
  • Business Quant data shows Other Working Capital Changes for RMD at $106.4 million in Q4 2025, -$2.3 million in Q3 2025, and -$47.0 million in Q2 2025.